Endometriosis Treatment Market Report Scope & Overview:

The Endometriosis Treatment Market was valued at USD 2.14 Billion in 2025 and is expected to reach USD 6.53 Billion by 2035, growing at a CAGR of 11.8% from 2026–2035.

There is continuous growth witnessed in the global market for treatment of endometriosis due to the high prevalence rate of the condition, increasing awareness of reproductive health among women and the rising demand for effective and tolerable treatment options to relieve chronic pelvic pain. The increased use of next-generation hormone therapy, non-surgical procedures and better drug delivery systems are expected to play increasingly important roles in shaping the management of this condition within hospitals and ambulatory facilities. All these are compounded by the continuing difficulties in managing chronic pelvic pain, delayed diagnosis of the condition and improving healthcare infrastructure in developed and developing countries.

It is important to mention that in March 2024, a paper presented in the Journal of Minimally Invasive Gynecology indicated that early use of hormone-based therapy resulted in a 78% decrease in symptoms' recurrence rate. The above-mentioned example shows how such clinical evidence impacts prescription patterns in gynecological practice.

Market Size and Forecast

• Market Size in 2026E: USD 2.39 Billion

• Market Size by 2035: USD 6.53 Billion

• CAGR: 11.8% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get more information on Endometriosis Treatment Market - Request Free Sample Report

Endometriosis Treatment Market Trends

• Hormonal therapies and oral contraceptives remain the preferred first-line treatment for endometriosis management.

• Minimally invasive laparoscopic procedures are improving diagnosis, treatment outcomes, and patient recovery.

• Development of targeted non-hormonal therapies is expanding future treatment options.

• Combined medical and surgical treatment approaches are enhancing long-term disease management.

• Growing awareness and screening programs are supporting earlier diagnosis and timely treatment.

The U.S. Endometriosis Treatment Market Outlook

The U.S. Endometriosis Treatment Market was valued at approximately USD 0.89 Billion in 2025 and is expected to reach approximately USD 2.71 Billion by 2035, growing at a CAGR of approximately 11.9%.

The United States holds the largest share in the worldwide endometriosis treatments market owing to its well-developed health care system, higher awareness of endometriosis, and funding for the study of women’s health. The market’s future growth is also expected to gain impetus from the presence of large pharma companies, high diagnoses, and adoption of minimally invasive surgeries. Favorable reimbursement policies, various clinical trials, and development of hormonal as well as non-hormonal treatments have together resulted in increased adoption of treatment options in the domestic market.

In March 2024, a global awareness initiative led by leading women's health organizations resulted in a 22% increase in early-stage endometriosis diagnoses across participating healthcare networks, directly contributing to higher treatment adoption rates. That kind of coordinated awareness effort continues to translate directly into measurable clinical impact within the U.S. healthcare system.

Endometriosis Treatment Market Segment Analysis

• By Type, the hormone therapy segment dominated the endometriosis treatment market with approximately 77.9% share in 2025, while the pain medication segment is expected to grow at a CAGR of 9.6%.

• By Drug Class, the gonadotropin-releasing hormone segment dominated the endometriosis treatment market with nearly 50.0% share in 2025, while the oral contraceptives segment is expected to maintain steady growth at a CAGR of 11.1%.

• By Route of Administration, the oral segment dominated the endometriosis treatment market with approximately 49.1% share in 2025, while the injectable segment is expected to grow at a CAGR of 12.2%.

• By Distribution Channel, the retail pharmacies segment dominated the endometriosis treatment market with approximately 52.3% share in 2025, and is also expected to grow at the fastest CAGR of 12.9%.

By Type, hormone therapy dominates, pain medication grow fastest

Market leadership was held by hormone therapy in 2025 since it was responsible for generating 77.9% of total revenue share due to the fact that it acts as an inhibitor of estrogen synthesis and control the symptoms of endometriosis. Hormone therapy is likely to continue holding this leading position in the future owing to the fact that patients need continuous management of their symptoms.

Pain medications accounted for 22.1% of revenue share in 2025, with a projected CAGR of 9.6% between 2026 and 2035. NSAIDs and analgesics have traditionally been used for symptom management, though they cannot cure the underlying disease and represent a comparatively less innovative segment of the broader treatment landscape.

By Drug Class, gonadotropin-releasing hormone dominates, oral contraceptives grow fastest

The share of the gonadotropin-releasing hormone class was 50.0% for 2025, due to their efficiency in preventing the release of hormones from the ovary as well as reducing the development of lesions in cases of advanced endometriosis. Medications belonging to this class are usually used in cycles, owing to their high efficiency in managing the disease.

Oral contraceptives formed a market share of around 28.5% and are anticipated to record a CAGR of 11.1% during the forecast period, owing to their easy access, low cost, and extensive use in treating early-stage endometriosis. NSAIDs held a 15.9% market share in 2025 and continue to provide complementary treatment, while the others category, holding a 5.6% share, reflects emerging treatment approaches and combination therapies.

By Route of Administration, oral segment dominates, injectable segment grows fastest

Oral drug delivery systems dominated the market in terms of mode of administration, contributing to about 49.1% of market share due to high acceptance among patients with regard to easy and non-invasive delivery systems, in addition to the availability of hormonal drugs and analgesics in oral dosage forms.

The Injectable segment accounted for 30.8% of the market, and it is expected to experience a CAGR of 12.2% during 2026-2035, owing to rising demand for sustained-release hormones which provide better efficacy as compared to oral dosing.

By Distribution Channel, retail pharmacies dominate, hospital pharmacies grow fastest

The retail pharmacies category was dominant in market share, accounting for around 52.3%, attributable to extensive market reach, convenience, and increased dispensation of medicines to patients with chronic conditions. Consumers tend to fill routine prescriptions for chronic diseases at retail pharmacies specifically.

The hospitals pharmacy made up about 29.9% of the total market size because of direct prescription from doctors and management of patients with more severe symptoms in the clinical setting. The other category, which is 17.8% and encompasses online pharmacies and others not classified traditionally as a pharmacy, is steadily increasing with the retail pharmacies projected to record the highest growth rate of 12.9%.

Regional Analysis

North America Endometriosis Treatment Market Insights

North America accounted for 41.87% of total global endometriosis treatment market revenue in 2025, a leadership position driven by the region's advanced healthcare system, high level of awareness regarding women's health, and superior diagnosis and treatment technologies. The US remains the dominant player in the North America market due to high rates of endometriosis diagnosis, the presence of specialty gynecologists, and advanced hormonal therapy and analgesic treatment options.

The region is projected to continue to dominate the global market share and revenue generation during the forecast period thanks to continued investment in women’s health facilities and increasing clinical trials. Canada also represents a smaller but reliable part of the regional demand due to the development of its gynecology care facilities.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Endometriosis Treatment Market Insights

Europe is currently the second-largest regional market for endometriosis treatment, supported by strong healthcare services, awareness initiatives, and well-established protocols for diagnosis and treatment. Germany, the UK, France, and Italy are among the key countries fueling regional growth, supported by stronger penetration of advanced treatment procedures and patient empowerment initiatives.

Public financing for healthcare, improvements in diagnosis, and the move towards less invasive treatment methods are all propelling the market forward within the region, thus placing Europe in a technically advanced, albeit restrained, growth market compared to Asia-Pacific and North America.

Asia Pacific Endometriosis Treatment Market Insights

Asia Pacific leads in revenue generation in the worldwide endometriosis treatment market, with expected growth of 11.8%. Within China, India, Japan, and South Korea, the developments in the healthcare service delivery system, heightened consciousness about reproductive disorders, and government-led campaigns will sustain the growth of the market in the region.

Expanding healthcare infrastructure, a growing patient population, and improved screening methods across these markets continue to support sustained regional expansion. Advances in treatment methodology and increased healthcare facility spending are further fueling market growth throughout the region.

MEA & Latin America Endometriosis Treatment Market Insights

The market for treating endometriosis has grown gradually in Latin America and the Middle East and Africa due to better health care facilities, higher awareness, and investments in women’s health care services. Brazil, Mexico, UAE, and Saudi Arabia have been witnessing positive trends with the availability of gynecology health care services.

Increased healthcare spending, combined with expanding training and patient education initiatives, continues to drive market growth across both regions. Adoption of effective treatment solutions and ongoing healthcare reforms is expected to contribute to future market development through 2035.

Market Dynamics

Growth Drivers: Rising disease awareness accelerate treatment adoption

Growing knowledge on endometriosis as a chronic disease in women, combined with progress made in diagnostic procedures and screening practices, continues to drive growth in the market. Growing education campaigns conducted by healthcare experts and organizations have played an important role in diagnosing endometriosis at an earlier stage, addressing one of the biggest issues in this field—under-diagnosis.

Greater availability of improved imaging and less invasive means of diagnosis has increased the accuracy of detection and treatment of endometriosis in many patients, thus increasing the demand for treatment. In March 2024, an awareness campaign spearheaded by renowned women's health organizations worldwide led to a 22% rise in the diagnosis of early-stage endometriosis among participating medical institutions.

Restraints: Limited long-term treatment efficacy hamper adoption

The existing treatment approaches for endometriosis involve mainly hormonal treatment and pain medication; however, these treatments might prove ineffective, since they do not ensure a satisfactory result for all patients. The recurrence of the symptoms after the treatment process, along with problems associated with fertility, hormones, and health in general, can actually be an obstacle to treatment and patient adherence to the treatment regimen.

Individual variability in treatment response, combined with the lack of a universal cure, adds further complexity to disease management. As a result, utilization of existing therapies remains constrained in certain patient populations, which continues to hamper broader market development.

Opportunities: Novel therapeutics and personalized treatment unlock growth potential

The endometriosis treatment market is expected to see favorable growth on the back of continued advancement in targeted therapies, the introduction of non-hormonal treatment options, and the broader movement of personalized medicine into routine clinical practice, a shift expected to continue reshaping the market in the near future. It is very clear from the facts stated above that there are plenty of needs for more innovations and therapies that cater to the clinical need, including biological drugs, selective progesterone receptor modulators, and gene technology with increased efficacy and reduced adverse effects.

In July 2024, one leading pharmaceutical company reported in a press release that their new non-hormonal drug has reduced chronic pelvic pain by 37% in Phase II clinical trials. This proves how well the next generation of drugs is revolutionizing the treatment of endometriosis. The use of principles of precision medicine is improving the success rate and satisfaction level of patients at a constant pace.

Recent Developments:

• 2024: In June 2024, Pfizer introduced an enhanced hormone therapy regimen designed to reduce pelvic pain and inflammation, strengthening its presence in the women's health therapeutics segment across developed and emerging markets.

• 2024: In October 2024, Bayer expanded its hormonal therapy portfolio for endometriosis treatment into Asia Pacific markets, collaborating with regional healthcare providers to enhance access to advanced therapeutic options across Japan and Australia.

• 2025: In January 2025, AbbVie expanded the clinical application of its oral GnRH antagonist therapy with improved dosing flexibility and long-term symptom control, enabling better patient adherence and outcomes across North America and Europe.

Endometriosis Treatment Market key players are:

• AbbVie Inc.

• Pfizer Inc.

• Bayer AG

• Takeda Pharmaceutical Company Limited

• Ferring Pharmaceuticals

• Teva Pharmaceutical Industries Ltd.

• Merck & Co., Inc.

• ObsEva SA

• Theramex

• Sanofi S.A.

• Gedeon Richter Plc.

• Lupin Limited

• Zydus Lifesciences Ltd.

• Dr. Reddy's Laboratories Ltd.

• Sun Pharmaceutical Industries Ltd.

• Viatris Inc.

• Organon & Co.

• Myovant Sciences GmbH

• Sumitomo Pharma Co., Ltd.

• Astellas Pharma Inc.

Endometriosis Treatment Market Report Scope: